Jefferies analyst Benjamin Jackson CFA has maintained their bullish stance on GALD stock, giving a Buy rating today.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Benjamin Jackson CFA’s rating is based on several strategic developments involving Galderma Group AG and L’Oreal. L’Oreal’s decision to increase its stake in Galderma to 20% signifies a strong vote of confidence in the company’s potential, especially in the fast-growing aesthetics market. This investment not only strengthens L’Oreal’s position but also suggests a deeper collaboration between the two companies, as Galderma considers nominating board members from L’Oreal to enhance business understanding and integration.
Additionally, the ongoing R&D partnership between Galderma and L’Oreal, with a focus on current diagnostic research projects, indicates a commitment to innovation and growth. These factors collectively suggest a positive outlook for Galderma, leading Benjamin Jackson CFA to recommend a Buy rating, reflecting the anticipated benefits from these strategic moves and the potential for future value creation.
According to TipRanks, Jackson CFA is a 3-star analyst with an average return of 12.2% and a 60.00% success rate. Jackson CFA covers the Healthcare sector, focusing on stocks such as Galderma Group AG, Roche Holding AG, and Sanofi.
In another report released today, Barclays also maintained a Buy rating on the stock with a CHF155.00 price target.